Etacept25 mg/0.5 ml

Etacept is a tumor necrosis factor (TNF)-alpha inhibitor (fusion protein biologic) indicated for the treatment of the following conditions:

Established / FDA-approved indications

• Rheumatoid arthritis (RA) in adults, to reduce signs and symptoms, induce major clinical response, inhibit progression of structural damage, and improve physical function. May be used alone or in combination with methotrexate.
• Polyarticular juvenile idiopathic arthritis (JIA) in patients aged 2 years and older.
• Psoriatic arthritis in adults, including use in combination with methotrexate in patients who do not respond adequately to methotrexate alone.
• Ankylosing spondylitis in adults.
• Moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy, and in pediatric patients 4 years and older.

Combination therapy

Etacept is commonly combined with methotrexate in rheumatoid arthritis and psoriatic arthritis for patients with an inadequate response to methotrexate monotherapy; this combination has demonstrated additional benefit over either agent alone.

Off-label / less-established uses

Etacept is not FDA-approved for inflammatory bowel disease (Crohn's disease or ulcerative colitis) and is generally not recommended for these conditions due to lack of efficacy. Uveitis and other TNF-mediated conditions are used off-label in select cases only under specialist supervision; such use should be individualized and is not a standard indication.

Each vial/prefilled syringe/autoinjector of Etanercept contains Etanercept, a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein, as the active ingredient, along with pharmaceutical excipients (such as sucrose, sodium chloride, and buffering agents) required for stability and injection.

Etacept is a genetically engineered fusion protein consisting of two soluble human TNF receptor p75 domains linked to the Fc portion of human IgG1. It is produced using recombinant DNA technology in a Chinese hamster ovary (CHO) mammalian cell expression system.

Etacept works by binding to and neutralizing tumor necrosis factor (TNF), a key pro-inflammatory cytokine involved in the pathogenesis of chronic inflammatory and autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis. It is administered by subcutaneous injection.

Etacept belongs to the therapeutic class of biologic disease-modifying antirheumatic drugs (bDMARDs), specifically the tumor necrosis factor (TNF)-alpha inhibitor class.

Etanercept is a soluble TNF receptor fusion protein that acts as a competitive inhibitor of TNF binding to its cell-surface receptors, thereby rendering TNF biologically inactive.

Mechanism of action

TNF and lymphotoxin are pro-inflammatory cytokines that bind to two distinct cell-surface receptors: TNFR1 (p55) and TNFR2 (p75). Etanercept is a dimeric fusion protein consisting of the extracellular ligand-binding portion of the human TNFR2 (p75) linked to the Fc portion of human IgG1. By binding TNF with higher affinity than the naturally occurring monomeric receptors, Etanercept inhibits TNF activity and modulates biologic responses controlled by TNF, including expression of adhesion molecules, serum cytokine levels (e.g., IL-6), and levels of matrix metalloproteinases involved in tissue remodeling responsible for cartilage destruction.

Pharmacokinetics

After subcutaneous injection, Etanercept is absorbed slowly, with peak serum concentrations reached approximately 48–72 hours after a single dose. Absolute bioavailability after subcutaneous administration is approximately 60%. The mean elimination half-life is approximately 70–100 hours (about 4 days), which supports once- or twice-weekly dosing.

Etacept is administered by subcutaneous (under-the-skin) injection only, never intravenously or intramuscularly. Recommended injection sites are the thigh, abdomen, or outer upper arm, with rotation of sites to reduce injection-site reactions. Allow the prefilled syringe or autoinjector to reach room temperature for about 15–30 minutes before injecting, and do not shake. Used needles and syringes should be disposed of in a puncture-resistant sharps container. See Dosage and Administration for dosing schedules by indication.

Clinically Significant Drug Interactions

• Anakinra: Concomitant use of Etacept with anakinra (an IL-1 receptor antagonist) is not recommended due to an increased risk of serious infections and neutropenia without added clinical benefit.
• Abatacept: Concurrent administration of Etacept with abatacept is not recommended, as it has been associated with an increased risk of serious infections compared with Etacept alone.
• Live vaccines: Live or live-attenuated vaccines should not be given concurrently with Etacept, as immune suppression may increase the risk of vaccine-related infection.
• Cyclophosphamide: Concomitant use of Etacept with cyclophosphamide has been associated with an increased risk of malignancy in clinical studies and is not recommended.
• Other biologic DMARDs: Combination with other TNF inhibitors or biologic agents is not recommended due to additive immunosuppression and infection risk.

Common Side Effects

• Injection-site reactions (redness, itching, pain, or swelling) — most common, usually mild and self-limiting
• Upper respiratory tract infections (sinusitis, pharyngitis)
• Headache
• Mild allergic reactions (rash)

Serious Side Effects

• Serious infections, including tuberculosis reactivation, invasive fungal infections, and serious bacterial or viral infections (see Precautions and Warnings)
• Malignancies, including lymphoma and, rarely, hepatosplenic T-cell lymphoma (see Precautions and Warnings)
• New-onset or worsening heart failure
• Demyelinating disorders (new onset or exacerbation)
• Hepatitis B reactivation in chronic carriers
• Cytopenias (rare): leukopenia, neutropenia, thrombocytopenia, aplastic anemia
• Lupus-like syndrome (rare, generally reversible after discontinuation)
• Severe allergic/hypersensitivity reactions, including angioedema and anaphylaxis (rare)

Patients should seek prompt medical attention for signs of infection (fever, persistent cough, night sweats), unusual bruising/bleeding, unexplained fatigue, or symptoms of heart failure (shortness of breath, swelling of ankles/legs).

Pregnancy

Etacept crosses the placenta, with increasing transfer in the third trimester. Available data have not established a clear association with major birth defects, but data remain limited. Etacept should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus; use should be discussed with and supervised by a physician. Infants exposed to Etacept in utero, particularly in the third trimester, may have altered immune responses; live vaccines should generally be avoided in such infants for a period after birth as advised by a pediatrician.

Lactation

Etacept has been detected in low levels in human breast milk. Limited data suggest minimal oral absorption by the infant, but a risk cannot be completely excluded. The decision to continue or discontinue breastfeeding during treatment with Etacept should be made in consultation with a physician, weighing the benefits of breastfeeding against the mother's clinical need for therapy.

Boxed Warnings

Serious Infections: Patients treated with Etacept are at increased risk of developing serious infections that may lead to hospitalization or death, including tuberculosis (TB) reactivation, invasive fungal infections (e.g., histoplasmosis), and bacterial or viral infections due to opportunistic pathogens. Patients should be screened for latent TB infection before starting and monitored during therapy. Etacept should be interrupted if a patient develops a serious infection.

Malignancy: Lymphoma and other malignancies, some fatal, have been reported in children and adolescents treated with TNF-blockers, including Etacept. Cases of hepatosplenic T-cell lymphoma, a rare and typically fatal malignancy, have been reported with TNF-blocker use, particularly in young male patients with inflammatory bowel disease receiving concomitant immunosuppressants (note: Etacept is not indicated for inflammatory bowel disease); a class-wide precaution regarding malignancy risk applies.

Other Precautions

• Heart failure: Etacept should be used with caution in patients with pre-existing heart failure, as it may cause new-onset or worsening congestive heart failure; monitor closely.
• Demyelinating disease: Rare cases of new-onset or exacerbation of central nervous system demyelinating disorders (e.g., multiple sclerosis-like symptoms) have been reported. Etacept should be avoided in patients with a history of such conditions.
• Hepatitis B reactivation: Patients should be screened for hepatitis B virus infection before starting Etacept; carriers should be monitored closely during and after treatment, as reactivation can occur.
• Live vaccines: Live vaccines should not be administered during treatment with Etacept due to the risk of secondary infection.
• Hematologic events: Rare cases of pancytopenia and aplastic anemia have been reported; monitor for signs of blood dyscrasias (unexplained bleeding, bruising, fever, pallor).
• Lupus-like syndrome: Rare, generally reversible upon discontinuation of Etacept.

No cases of dose-limiting toxicity have been reported with Etacept in clinical trials, even at doses higher than recommended. In the event of a suspected overdose, patients should seek immediate medical attention or contact emergency services/poison control for evaluation. Management is supportive; there is no specific antidote for Etacept overdose. Patients should be monitored closely for any signs of adverse effects, particularly infection.

Etacept should be stored in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze. Keep the product in its original carton to protect from light until time of use. Do not shake. Keep out of reach of children. Consult the specific product label for any manufacturer-specific allowance for limited room-temperature storage.

Elderly

No overall differences in effectiveness were observed between elderly and younger patients receiving Etacept; however, because of a generally higher incidence of infections and malignancies in the elderly population, caution should be exercised.

Renal and Hepatic Impairment

Specific dose adjustments for Etacept have not been established in renal or hepatic impairment; use with caution and appropriate monitoring.

Immunocompromised Patients

Etacept should be used with caution in patients with a history of recurrent infections or underlying conditions that predispose to infection, given its immunosuppressive mechanism.

See Pediatric Uses and Pregnancy and Lactation sections for additional population-specific guidance.

The duration of treatment with Etacept is individualized based on the condition being treated, clinical response, and tolerability. Etacept is generally intended for long-term, continuous use to maintain disease control in chronic inflammatory conditions such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis. Clinical response is typically assessed within the first 3 months of therapy; treatment should be reconsidered if no meaningful response is observed within this period. Continued use requires periodic clinical evaluation and monitoring for infections, malignancy, and other adverse effects.

Certain presentations of Etacept (multiple-dose vials of lyophilized powder) require reconstitution before use. Reconstitute using only the supplied sterile diluent (bacteriostatic water for injection); inject the diluent slowly into the vial, aiming the stream against the glass wall to avoid excess foaming, and gently swirl (do not shake) until the powder is completely dissolved, forming a clear, colorless to pale yellow solution. Allow the solution to reach room temperature before use and use within the time specified on the product labeling. Prefilled syringes and autoinjector presentations of Etacept are ready to use and do not require reconstitution.

Etanercept is classified as a biologic disease-modifying antirheumatic drug (bDMARD) and, more specifically, a tumor necrosis factor (TNF)-alpha inhibitor (TNF receptor fusion protein).

Etanercept is a soluble fusion protein combining the human TNF receptor p75 with the Fc fragment of human IgG1. It competitively binds circulating TNF-alpha (and lymphotoxin-alpha), preventing TNF from interacting with its native cell-surface receptors. This neutralizes TNF's pro-inflammatory signaling, reducing downstream inflammatory cascades responsible for joint and skin inflammation in diseases such as rheumatoid arthritis and plaque psoriasis.

B

Etacept is approved for use in children 2 years of age and older for polyarticular juvenile idiopathic arthritis, at a weight-based dose of 0.8 mg/kg subcutaneously once weekly (maximum 50 mg per dose), or a fixed 50 mg once weekly for patients weighing 63 kg or more.

Etacept is also approved for moderate to severe plaque psoriasis in pediatric patients 4 years of age and older, at the same weight-based dosing regimen.

Safety and efficacy of Etacept have not been established in children younger than 2 years of age for juvenile idiopathic arthritis or younger than 4 years of age for plaque psoriasis, or for other pediatric indications not listed above. Pediatric patients receiving Etacept should be monitored closely for infections and growth/development, and vaccination status should be updated (avoiding live vaccines) prior to starting therapy where possible.